Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C4H6N2S
CAS Number:
Molecular Weight:
114.17
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
108646
eCl@ss:
39161002
grade
pharmaceutical primary standard
API family
methimazole
manufacturer/tradename
USP
mp
144-147 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CN1C=CNC1=S
InChI
1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
InChI key
PMRYVIKBURPHAH-UHFFFAOYSA-N
Gene Information
human ... TPO(7173)
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Methimazole USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Methimazole Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
flash_point_f
Not applicable
flash_point_c
Not applicable
target_organs
Endocrine system
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1A - Skin Sens. 1 - STOT RE 2
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Clementi et al.
American journal of medical genetics, 83(1), 43-46 (1999-03-17)
We report on a further case of congenital anomalies in a child exposed to methimazole during the first trimester of pregnancy (from first to seventh gestational week), and define a specific malformation pattern related to prenatal methimazole exposure and consisting
Fernando Bolaños et al.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 54(4), 307-310 (2002-11-06)
Long-term thionamide treatment is considered one of the main resources for Graves' hyperthyroidism. Although a 54.2% remission rate in patients so treated in Mexico was previously reported, most articles have shown a wide variation over time. In the present article
K E Hill et al.
New Zealand veterinary journal, 62(4), 208-213 (2013-12-20)
To determine the pharmacokinetics of a novel lipophilic formulation of transdermal methimazole compared to oral carbimazole. Healthy cats received 5 mg carbimazole orally every 12 hours for 13 treatments (n=6), then received transdermal methimazole (n=5) at a dose of 5 mg, then
Jeanne M Chattaway et al.
The Annals of pharmacotherapy, 41(6), 1018-1022 (2007-05-17)
To evaluate the evidence supporting the use of propylthiouracil (PTU) versus methimazole for the treatment of Graves' disease during pregnancy. An English-language literature search was conducted using MEDLINE (1966-March 2007). Identified articles were then reviewed for additional sources. Search terms
Roberto Gastaldi et al.
The Journal of pediatrics, 164(5), 1189-1194 (2014-02-13)
To evaluate clinical and biochemical features of 115 children (98 female, mean age 11.3 ± 3.5 years) with Graves disease to identify possible determinants of remission. We defined as positive outcome the improvement of clinical features and restoration of euthyroidism
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 1411005-200MG | 04061833860526 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service